Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Annals of Oncology.
Times cited: 803
Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer.
Journal of Clinical Oncology.
Times cited: 16
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.
Times cited: 1218